|
|
||||||||
J Thorac Cardiovasc Surg 2005;130:433-437
© 2005 The American Association for Thoracic Surgery
General Thoracic Surgery |
a Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
b Department of Cardio Thoracic Surgery, Dokkyo University School of Medicine, Tochigi, Japan.
Received for publication August 1, 2004; revisions received January 24, 2005; accepted for publication February 10, 2005. * Address for reprints: Tatsuya Yoshimasu, MD, PhD, Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, 811-1, Kimiidera, Wakayama, Wakayama 641-8509, Japan. (Email: yositatu{at}mail.wakayama-med.ac.jp).
| Abstract |
|---|
|
|
|---|
METHODS: Our previous study revealed that the mediastinal sentinel lymph node, defined as the regional mediastinal lymph node, consisted of nodes 2, 3, or 4 in right upper lobe cancers; 3, 7, or 8 in right lower lobe cancers; 4, 5, or 7 in left upper lobe cancers; and 4, 7, or 8 in left lower lobe cancers. On the basis of these findings, we pathologically investigated one representative lymph node at each of the 3 levels dissected during surgical intervention in 69 patients with non-small cell lung cancer from September 1993 through December 2002. Fifty-eight patients with lung cancer underwent lobectomies with limited mediastinal lymph node dissection according to this strategy.
RESULTS: Mediastinal lymph node recurrence was observed in only one patient during 41 ± 25 months (maximum, 98 months) of follow-up. The cancer-specific 5-year survivals were 96.6% in patients with pathologic stage IA disease (n = 31) and 67.4% in patients with stage IB disease (n = 16).
CONCLUSION: These results suggested that limited mediastinal lymph node dissection is applicable to patients with non-small cell lung cancer whose regional mediastinal lymph nodes are not metastatic.
| Introduction |
|---|
|
|
|---|
|
Sentinel lymph node mapping techniques have been extensively studied in melanoma and breast cancers,
13
and they are now applied to most solid tumors. Usually these techniques involve the preoperative injection of a blue dye or radioisotope into the peritumoral tissue, which allows the sentinel lymph nodes to be detected during surgical intervention. However, there are some difficulties with these methods in their application to lung cancer surgery. First, preoperative computed tomography-guided injections of a radioisotope or blue dye into the lung are somewhat troublesome; second, blue dye is not so beneficial for anthracotic lymph nodes.
We
4
previously investigated which mediastinal lymph node levels should be examined during surgical intervention to diagnose N2 or less than N2 disease in patients with bronchogenic carcinomas. With primary tumors, 3 mediastinal lymph node levels were selected for each lobe and defined as regional mediastinal lymph nodes; the idea of the regional mediastinal lymph node is quite similar to that of the sentinel lymph node. However, investigation of the regional mediastinal lymph node is more practical and convenient than sentinel lymph node examination by means of tracer-guided sentinel lymph node biopsy techniques because regional mediastinal lymph nodes are examined pathologically during surgical intervention without any special equipment. We suggested that if the regional mediastinal lymph nodes are not metastatic, dissection of mediastinal lymph nodes could be stopped at this point without the additional mediastinal lymph node dissection.
Thus, a prospective study of limited mediastinal lymph node dissection on the basis of the idea of the regional mediastinal lymph node was commenced in 1993. This report shows the follow-up results of this study and discusses the validity of the proposed method.
| Patients and Methods |
|---|
|
|
|---|
|
The patients were followed up every month within the first 6 months after surgical intervention at an outpatient clinic and every 2 months thereafter. During the follow-up period, plain chest x-ray films and serum tumor marker levels were obtained. Brain, chest, and abdominal computed tomographic scans, as well as bone scintigraphies, were performed every 6 months to detect tumor recurrence. The mean follow-up time of the patients was 41 ± 25 months (range, 298 months).
All values are given as the mean ± standard deviation. The Kaplan-Meier method was used to evaluate patient prognosis.
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Sentinel lymph node-mapping procedures have already been applied to most solid malignant tumors.
13,12
In breast cancers sentinel lymph node-mapping procedures are becoming the standard operative procedure. Liptay and associates
13
reported that radioisotope (RI)-guided sentinel lymph node mapping techniques are applicable for lung cancer surgery. It has also been reported that precise histologic examinations of sentinel lymph nodes yield more accurate diagnoses of lymph node metastasis. Schmidt and colleagues
14
revealed the accuracy of RI-guided sentinel lymph node mapping techniques in lung cancer. However, the validity of sentinel lymph node mapping techniques for limited mediastinal lymph node dissection has yet to be determined.
The 3 determined levels in the mediastinal lymph nodes (Table 1) were recognized as the regional mediastinal lymph nodes for each lobe. The 3 levels are extremely consistent with the anatomic lymphatic efferent pathways from each lung.
15,16
The patterns of mediastinal lymph node metastasis reported in other reports are relatively similar to our results,
11,16,17
and therefore the idea of determining and examining 3 levels of mediastinal lymph nodes during surgical intervention is similar to the method of sentinel lymph node mapping. However, our method seems more practical and convenient in the clinical setting than sentinel lymph node mapping, which requires special equipment.
Table 1 compares the settings of limited (regional) mediastinal lymph node dissection and standard lymph node dissection. Limited (regional) mediastinal lymph node dissection is apparently less invasive compared with standard lymph node dissection, except for the left upper lobe.
Residual mediastinal lymph node recurrence was experienced in one case with an adenocarcinoma in the left lower lobe and partial involvement of the left upper lobe. The patient underwent a left lower lobectomy and partial resection of the left upper lobe with limited (regional) mediastinal dissection of lymph nodes 4, 7, and 8. Recurrence in lymph nodes 1, 2, 3, and 5 was observed 13 months after surgical intervention. It is likely that we failed to detect the lymph node metastasis in level 5, which is the regional lymph node of the left upper lobe. Therefore, our method should not be applied to patients with extralobar involvement.
Rare cases with extraregional skip metastasis have been reported previously (ie, metastasis to the level 7 nodes in upper lobe cancers). Anatomic investigation, including lymph scintigraphy, revealed that direct lymphatic flow to extraregional lymph nodes existed in some patients.
11,15
Although there was no extraregional nodal recurrence in our patients, we surmise that the small possibility of extraregional skip metastasis exists in the limited mediastinal lymph node dissection.
The survivals of the patients who underwent limited (regional) mediastinal lymph node dissection showed no inferiority to those in the latest report in Japan on lung cancer.
6
There was no mediastinal lymph node recurrence in the 57 patients whose indications were thought to be appropriate. These findings indicate the applicability and validity of limited mediastinal lymph node dissection in selected patients with NSCLC according to intraoperative histologic examinations.
From 1999, a prospective randomized trial of nodal sampling versus complete mediastinal nodal dissection was conducted by the American College of Surgeons Oncology Group (ACOSOG), and it was recently closed. This study consisted of 1000 patients (one arm = 500 patients). It is expected that the follow-up results will confirm the validity of the nodal sampling method.
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
P. Misthos, E. Sepsas, J. Kokotsakis, I. Skottis, and A. Lioulias The Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., November 1, 2008; 86(5): 1626 - 1630. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhong, X. Yang, J. Bai, J. Yang, C. Manegold, and Y. Wu Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 187 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Watanabe, T. Mishina, S. Ohori, T. Koyanagi, S. Nakashima, T. Mawatari, Y. Kurimoto, and T. Higami Is video-assisted thoracoscopic surgery a feasible approach for clinical N0 and postoperatively pathological N2 non-small cell lung cancer? Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 812 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muraoka, S. Akamine, T. Oka, T. Tagawa, A. Nakamura, T. Tsuchiya, T. Hayashi, and T. Nagayasu Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 356 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Allen Mediastinal lymph node dissection for non-small cell lung cancer J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 241 - 242. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |